Post on 14-Jan-2016
description
transcript
A Report from ASCO-GI 2008and ASCO 2007
Up-to-Date Review of the Treatment of Adjuvant Colorectal Cancer
A Report from ASCO-GI 2008and ASCO 2007
Up-to-Date Review of the Treatment of Adjuvant Colorectal Cancer
Axel Grothey, MDProfessor of Oncology
Mayo Clinic College of MedicineRochester, MN
Axel Grothey, MDProfessor of Oncology
Mayo Clinic College of MedicineRochester, MN
History of Adjuvant Therapy of Colon Cancer
• 5-FU/lev superior to surgery alone
• 5-FU/LV superior to surgery alone
• 5-FU/LV superior to 5-FU/lev
• 6- and 12-month treatment cycles equivalent
• Lev unnecessary
• High-dose and low-dose LV equivalent
• Monthly and weekly treatment equivalent
• LV5FU2 and monthly bolus equivalent
1990 1994 1998 2002
Moertel et al. Ann Intern Med. 1995;122:321.Francini et al. Gastroenterol. 1994;106:899.
Wolmark et al. Proc Am Soc Clin Oncol. 1996;15:205. AbstractO’Connell et al. J Clin Oncol. 1998;16:295.
Haller et al. Proc Am Soc Clin Oncol. 1998;17:256a. Abstract 982.Andre et al. Proc Am Soc Clin Oncol. 2002. Abstract 529.
3 Year DFS vs 5 Year OS
0.5
0.55
0.6
0.65
0.7
0.75
0.8
0.5 0.55 0.6 0.65 0.7 0.75 0.8
Disease Free Survival
Ove
rall
Sur
viva
l
P = 0.90
5-yr OS = 0.0002 + 0.998* 3-yr DFS
May 05, 2004: ODAC recommends3-yr DFS as new regulatory endpointfor FULL approval in adjuvant colon cancer
Sargent, et al. J Clin Oncol 2005;23:8664–8670.
5-FU: Historical Standardin the Adjuvant Setting
5-FU: Historical Standardin the Adjuvant Setting
1IMPACT Investigators, Lancet 1995;345:939–44.2Wolmark N, et al. J Clin Oncol 1993;11:1879–87.
3QUASAR Group. Lancet 2000;355:1588–96.4André T, et al. J Clin Oncol 2003;21:2896–903.
3-year disease-free survival (%)
Observation1
5-FU/high-dose LV (Mayo)2
5-FU/low-dose LV (Mayo)3
LV5FU24
Stage II and III colon cancer patients
6 months 5-FU/LV (Mayo)1
55 60 65 70 75
Beyond 5-FU in the Adjuvant SettingBeyond 5-FU in the Adjuvant Setting
Completed studies:
• Oxaliplatin (MOSAIC, NSABP C-07)
• Irinotecan (CALGB 89803, ACCORD-2, PETACC-3)
• Capecitabine (X-ACT)
Ongoing studies:
• CAPOX (XELOXA)
• Bevacizumab (NSABP C-08, AVANT, E5202)
• Cetuximab (N0147, PETACC-8)
Completed studies:
• Oxaliplatin (MOSAIC, NSABP C-07)
• Irinotecan (CALGB 89803, ACCORD-2, PETACC-3)
• Capecitabine (X-ACT)
Ongoing studies:
• CAPOX (XELOXA)
• Bevacizumab (NSABP C-08, AVANT, E5202)
• Cetuximab (N0147, PETACC-8)
MOSAIC: Study DesignMOSAIC: Study Design
Primary end-point: disease-free survival
Secondary end-points: safety, overall survival
Primary end-point: disease-free survival
Secondary end-points: safety, overall survival
R
LV5FU2
FOLFOX4(LV5FU2 + oxaliplatin 85 mg/m²)
(N =1,123)
(N =1,123)
LV5FU2, Leucovorin 200 mg/m2 iv over 2 hours followed by 5-fluorouracil 400 mg/m2 bolus and 5-fluorouracil 600 mg/m2 iv over 22 hours on Days 1 and 2, every 14 days;
FOLFOX4, LV5FU2 + oxaliplatin 85 mg/m2 iv over 2 hours on Day 1
N = 2,246
Enrollment:Oct 1998–Jan 2001 (146 centres; 20 countries)
• Completely resected colon cancer
• Stage II, 40%; Stage III, 60%
• Age 18–75 years
• KPS ≥60
• No prior chemotherapy
Disease-free Survival: ITTDisease-free Survival: ITT
Data cut-off: June 2006Disease-free survival (months)
FOLFOX4
LV5FU2
Pro
babi
lity
1.0
0.8
0.6
0.4
0.2
0
0.9
0.7
0.5
0.3
0.1
0 6 12 18 24 6030 36 42 48 54
Events
FOLFOX4 304/1,123 (27.1%)
LV5FU2 360/1,123 (32.1%)
HR [95% CI]: 0.80 [0.68–0.93]
5.9%
P = 0.0035.3%
De Gramont A, et al. ASCO 2007. Abstract #4007.
Disease-free Survival:Stage II and Stage III Patients
Disease-free Survival:Stage II and Stage III Patients
Data cut-off: June 2006
HR [95% CI] P - value
Stage II 0.84 [0.62–1.14] 0.258
Stage III 0.78 [0.65–0.93] 0.005
FOLFOX4 stage II
LV5FU2 stage II
FOLFOX4 stage III
LV5FU2 stage III
Months
Pro
babi
lity
1.0
0.8
0.6
0.4
0.2
0
0.9
0.7
0.5
0.3
0.1
0 6 12 18 24 6030 36 42 48 54 66 72
3.8%
7.5%
P = 0.258
P = 0.005
De Gramont A, et al. ASCO 2007. Abstract #4007.
MOSAIC: Disease-free Survival –Final Update
MOSAIC: Disease-free Survival –Final Update
5-year DFS %
HR [95% CI] P - value FOLFOX4 LV5FU2
ITT (overall population) 73.3 67.4 0.80
[0.68–0.93]
0.003
Stage III 66.4 58.9 0.78
[0.65–0.93]
0.005
Stage II 83.7 79.9 0.84
[0.62–1.14]
0.258
High-risk stage II N = 576 82.1 74.9 0.74
[0.52–1.06]
—
Low-risk stage II N = 323 86.3 89.1 1.22
[0.66–2.26]
—
Data cut-off: June 2006
De Gramont A, et al. ASCO 2007. Abstract #4007.
“High-risk” Stage II Colon Cancer“High-risk” Stage II Colon Cancer
• Clinico-pathological parameters (MOSAIC)
- T4 tumors
- Obstruction/perforation
- Lymphatic or vascular invasion
- Undifferentiated histology
- Less than 10 (12) Ln examined
• Molecular parameters
- LOH 18q
- MSS
- Other?
• Clinico-pathological parameters (MOSAIC)
- T4 tumors
- Obstruction/perforation
- Lymphatic or vascular invasion
- Undifferentiated histology
- Less than 10 (12) Ln examined
• Molecular parameters
- LOH 18q
- MSS
- Other?De Gramont A, et al. ASCO 2007. Abstract #4007.
Long-term SafetyLong-term Safety
(% patients)
FOLFOX
5.3
LV5FU2
5.7
0
10
20
30
40
50
60
DuringTx
6months
1-year 2-year 3-year 4-year
Grade 1
Grade 2
Grade 3
Data cut-off: January 2007
Second cancer
Peripheral Sensory Neuropathy
Evaluable patients
N = 811
Grade 0 84.3%
Grade 1 12.0%
Grade 2 2.8%
Grade 3 0.7%
De Gramont A, et al. ASCO 2007. Abstract #4007.
Overall Survival: ITTOverall Survival: ITT
Data cut-off: January 2007
Overall survival (months)
FOLFOX4
LV5FU2
Pro
babi
lity
1.0
0.8
0.6
0.4
0.2
0
0.9
0.7
0.5
0.3
0.1
0 6 12 18 24 6030 36 42 48 54 66 9672 78 84 90
Events
FOLFOX4 243/1,123 (21.6%)
LV5FU2 279/1,123 (24.8%)
HR [95% CI]: 0.85 [0.72–1.01]
2.6%
P = 0.057
6 yrs: 78.6% vs. 76.0%
De Gramont A, et al. ASCO 2007. Abstract #4007.
Overall Survival: Stage II and Stage IIIOverall Survival: Stage II and Stage III
Data cut-off: January 2007
FOLFOX4 stage II
LV5FU2 stage II
FOLFOX4 stage III
LV5FU2 stage III
Overall survival (months)
Pro
babi
lity
1.0
0.8
0.6
0.4
0.2
0
0.9
0.7
0.5
0.3
0.1
0 6 12 18 24 6030 36 42 48 54 66 9672 78 84 90
HR [95% CI]
Stage II 1.00 [0.71–1.42]
Stage III 0.80 [0.66–0.98]
0.1%
4.4%
P = 0.996
P = 0.029
De Gramont A, et al. ASCO 2007. Abstract #4007.
Take-Home Messages MOSAICTake-Home Messages MOSAIC
• DFS benefit for FOLFOX is maintained over 5 years
• Significant OS benefit for stage III, but NOT for unselected stage II patients
• “High-risk” stage II with trend toward better DFS with FOLFOX, but clinical consequence unclear
• No increased rate of secondary cancers, but more deaths of cancer in FOLFOX group (21 vs. 11)
• Even 4 years after FOLFOX, 3.5% of patients still have grade 2/3 neurotoxicity (+12% grade 1)
FOLFOX is standard adjuvant therapy for stage III and can be considered for high-risk stage II CC
• DFS benefit for FOLFOX is maintained over 5 years
• Significant OS benefit for stage III, but NOT for unselected stage II patients
• “High-risk” stage II with trend toward better DFS with FOLFOX, but clinical consequence unclear
• No increased rate of secondary cancers, but more deaths of cancer in FOLFOX group (21 vs. 11)
• Even 4 years after FOLFOX, 3.5% of patients still have grade 2/3 neurotoxicity (+12% grade 1)
FOLFOX is standard adjuvant therapy for stage III and can be considered for high-risk stage II CC
FU RestLV 500
FU 500
RestLV 500
OHP 8585 2hr2hr
500
Week 1 2 3 4 5 6 7 8
R
NSABP C-07
x3
N = 2,407
Endpoint3yr DFS
Accrual 02/00 - 11/02
RP
FLOX
Kuebler JP, et al. J Clin Oncol 2007;25:2198–2204.
Ev # 3yr DFSFLOX 272 76.5%FULV 332 71.6%
P < 0.004HR: 0.79 [0.67 – 0.93]
21 % risk reduction
C-07: DFS
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4
Kuebler JP, et al. J Clin Oncol 2007;25:2198–2204.
3y DFS Δ HR
C-07 76.5 % 4.9 % 0.79
MOSAIC 77.9 % 5.1 % 0.77
C-07 and MOSAIC - Oxaliplatin benefit
De Gramont A, et al. ASCO 2007. Abstract #4007.Kuebler JP, et al. J Clin Oncol 2007;25:2198–
2204.
Cross-Study ComparisonToxicity: MOSAIC / C-07Cross-Study ComparisonToxicity: MOSAIC / C-07
FOLFOX 4
(MOSAIC)
FLOX
(C-07)
Gr 3-4 Neutropenia41%
(2% neut. fever)4% (?)
Gr 3-4Diarrhea
11% 38%
Gr 3 Neuro(cum oxali)
12.4%(1,020 mg/m2)
8%(765 mg/m2)
All Cause Mortality 0.5% 1%
De Gramont A, et al. ASCO 2007. Abstract #4007.Kuebler JP, et al. J Clin Oncol 2007;25:2198–
2204.
Abstract 347
Ramanathan RK, André T, Rothenberg ML, de Gramont A,
Tournigand C, Goldberg RM, Gupta S
Diabetes Mellitus and the Incidence and Time to Onset of Oxaliplatin-Induced
Peripheral Sensory Neuropathy (PSN) in Patients with Colorectal Cancer: A Pooled
Analysis of Three Randomized Studies
Pooled AnalysisPooled Analysis
• Data from 3 randomized clinical trials including FOLFOX4
• EFC3313 (MOSAIC): 5-FU and LV (LV5–FU2) + oxaliplatin as adjuvant therapy in CRC
• EFC4584: Three-arm study of LV5–FU2, LV5–FU2 with oxaliplatin, or oxaliplatin alone as second-line therapy of metastatic CRC
• EFC2962: Phase II/III study of LV5FU2 + oxaliplatin first-line
• PSN data from the overall study population with or without diabetes were analyzed for:
• Incidence and time to onset of PSN
• Trends indicating clinically relevant differences in the incidence and severity of PSN
• Data from 3 randomized clinical trials including FOLFOX4
• EFC3313 (MOSAIC): 5-FU and LV (LV5–FU2) + oxaliplatin as adjuvant therapy in CRC
• EFC4584: Three-arm study of LV5–FU2, LV5–FU2 with oxaliplatin, or oxaliplatin alone as second-line therapy of metastatic CRC
• EFC2962: Phase II/III study of LV5FU2 + oxaliplatin first-line
• PSN data from the overall study population with or without diabetes were analyzed for:
• Incidence and time to onset of PSN
• Trends indicating clinically relevant differences in the incidence and severity of PSN
Ramanathan 2008 ASCO GI abstract # 347
Incidence and Severity of PSNIncidence and Severity of PSN
PSNAll Patients
(N = 1,585)
DM Patients
(N = 135)
Grade 1 45.2 46.7
Grade 2 28.4 26.7
Grade 3 13.0 12.6
Ramanathan 2008 ASCO GI abstract # 347
Probability of PSN by Cumulative Dose
EFC3313: any grade EFC3313: grade ≥ 3
EFC4584: any grade EFC4584: grade ≥ 3Ramanathan 2008 ASCO GI abstract # 347
Conclusions FOLFOX in DiabeticsConclusions FOLFOX in Diabetics
• In CRC trials with FOLFOX4 no difference in:
- the probability of developing PSN nor
- the severity of grade between all treated patients
and the subset with diabetes mellitus was observed
• This data suggests patients with diabetes mellitus have no increased risk of developing cumulative neurotoxicity
• In CRC trials with FOLFOX4 no difference in:
- the probability of developing PSN nor
- the severity of grade between all treated patients
and the subset with diabetes mellitus was observed
• This data suggests patients with diabetes mellitus have no increased risk of developing cumulative neurotoxicity
Ramanathan 2008 ASCO GI abstract # 347
CALGB 89803: DFS and OS Not Improvedwith IFL in Stage III Colon Cancer
CALGB 89803: DFS and OS Not Improvedwith IFL in Stage III Colon Cancer
Saltz L, et al. J Clin Oncol 2007;25:3456–61
OS = overall survival; IFL = irinotecan, 5-FU plus leucovorin
1.0
0.8
0.6
0.4
0.2
0
1.0
0.8
0.6
0.4
0.2
0
Pro
port
ion
dise
ase-
free
Pro
port
ion
surv
ivin
g0 1 2 3 4 5 6 7
Years0 1 2 3 4 5 6 7
Years
N Events
FU/LV 629 227IFL 635 248
P (stratified) = 0.85 (1-sided)
N Events
FU/LV 629 171IFL 635 181
P (stratified) = 0.74 (1-sided)
FU/LVIFL
FU/LVIFL
ACCORD-02Irinotecan in High-risk Stage III Colon Cancer
ACCORD-02Irinotecan in High-risk Stage III Colon Cancer
• 400 patients with resected high risk stage III colon cancer (N2 or N1 with occlusion/perforation)
• Accrual completed in Spring 2002
• Stratified:- Center- N stage- Delay to chemotherapy- Age
• 400 patients with resected high risk stage III colon cancer (N2 or N1 with occlusion/perforation)
• Accrual completed in Spring 2002
• Stratified:- Center- N stage- Delay to chemotherapy- Age
RANDOMIZE LV5FU2
FOLFIRI:• LV5FU2• CPT-11 180 mg/m2
on day 1
12 cycles planned
Ychou M, et al. J Clin Oncol 2005;(Suppl. 16):246s (Abstract 3502)
ACCORD-02: DFS Not Improved with FOLFIRI in High-risk Colon Cancer
ACCORD-02: DFS Not Improved with FOLFIRI in High-risk Colon Cancer
Ychou M, et al. J Clin Oncol 2005;(Suppl. 16):246s (Abstract 3502)
1.0
0.8
0.6
0.4
0.2
00 1 2 3 4 5 6
Years
Est
imat
ed p
roba
bilit
y HR = 1.19 (95% CI: 0.90–1.59)P = 0.22
LV5FU2 60FOLFIRI 51
3-year DFS (%)
Stratification:
• Stage II vs. III
• Center
RANDOMIZATION
Day 1 Day 2
FA 200 mg/m2
5-FU bolus 400 mg/m2
5-FU CI 600 mg/m2
Day 1 Day 2
Irinotecan 180 mg/m2
LV5FU2
LV5FU2 as above
F
IFRepeat q 2 weeks
for 12 Cycles
PETACC-3: Study Design
210 pts treated with AIO regimen ± irinotecan within given centers will be presented later.
Van Cutsem E, et al. J Clin Oncol 2005; 23:(Suppl. 16):3s (Abstract LBA8)
PETACC-3: Results Stage IIIPETACC-3: Results Stage III
HR (95% CI)
P-value
DFS 0.89 0.091(0.77-1.11)
RFS 0.86 0.045(0.75-1.00)
Van Cutsem E, et al. J Clin Oncol 2005; 23:(Suppl. 16):3s (Abstract LBA8)
PETACC-3: DFS not significantly improved with FOLFIRI in stage IIIPETACC-3: DFS not significantly improved with FOLFIRI in stage III
Van Cutsem E, et al. J Clin Oncol 2005; 23:(Suppl. 16):3s (Abstract LBA8)
1.0
0.9
0.8
0.7
0.6
0.5
0
Est
imat
ed p
roba
bilit
y
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48Months
FOLFIRI 1,044 63.35-FU/LV 1,050 60.3
HR=0.89 (95% CI: 0.77–1.11)
P = 0.091
3-year DFS (%)
DFS = disease free survivalHR = hazard ratio; CI = confidence interval
N
X-ACT Trial - DesignX-ACT Trial - Design
Endpoints- DFS- RFS- overall survival (OS)- tolerability (NCIC CTG)- pharmacoeconomics- quality of life (QoL)
Chemo-naïve stage III colon cancer,resection 8 weeks
Capecitabine1 250mg/m2 twice daily,
d1–14, q21d N = 1,004
Bolus 5-FU / LV5-FU 425mg/m2 plus
LV 20mg/m2, d1–5, q28dN = 983
Recruitment1998–2001
24 weeks
Twelves et al., N Engl J Med 2005
X-ACT: 5-year DFS (median follow-up 6.8 years)
X-ACT: 5-year DFS (median follow-up 6.8 years)
5-year
DFS (%)
Capecitabine 1, 004 60.8
5-FU/LV 983 56.7
1.0
0.8
0.6
0.4
0.2
00 6 42 48 78 96
Months
HR = 0.88 (95% CI: 0.77–1.01)NI margin 1.20
12 18 24 30 36 54 60 66 72 84 90
ITT population
Est
imat
ed p
roba
bilit
y
ITT (intent-to-treat) population; NI = non-inferiority
Twelves C, et al. Eur J Cancer Suppl 2007;5:1 (Abstract 1LB)
102
N
Test of non-inferiority P < 0.0001Test of superiority P = 0.0682
X-ACT: 5-year OS (median follow-up 6.8 years)
X-ACT: 5-year OS (median follow-up 6.8 years)
HR = 0.86 (95% CI: 0.74–1.01)NI margin 1.14
ITT population
0 6 42 48 78 96
Months
12 18 24 30 36 54 60 66 72 84 90 102
1.0
0.8
0.6
0.4
0.2
0
Est
imat
ed p
roba
bilit
y
Test of non-inferiority P = 0.000116Test of superiority P = 0.06
5-year
OS (%)
Capecitabine 1, 004 71.4
5-FU/LV 983 68.4
N
Twelves C, et al. Eur J Cancer Suppl 2007;5:1 (Abstract 1LB)
Neutropenia
Nausea/
vomitin
g
Stomatitis
Diarrhea
Febrile
neutropenia HFS
Pat
ient
s (%
)
Scheithauer W, et al. Ann Oncol 2003;14:1735–43
**
* *
*P < 0.001HFS = hand foot syndrome
Capecitabine (N = 993)
5-FU/LV (N = 974)
Grade 3/4 adverse events
X-ACT: Improved Safety with CapecitabineX-ACT: Improved Safety with Capecitabine
50
40
30
20
10
0
Chemo/radiotherapy-naïve
stage III colon cancer
Bolus 5-FU/LVMayo Clinic or Roswell Park
CAPOXCapecitabine 1,000mg/m2 b.i.d. days 1–15
Oxaliplatin 130mg/m2 day 1 q3w
Schmoll HJ, et al. J Clin Oncol 2007;25:4217–23
XELOXA: Phase III Trial of CAPOX in the Adjuvant Setting
XELOXA: Phase III Trial of CAPOX in the Adjuvant Setting
• Primary endpoint: disease-free survival• Primary endpoint: disease-free survival
N = 944
N = 942
RANDO MISATION
Duration of therapy: 24 weeks
Grade 3/4 Adverse Events
Pat
ient
s (%
)
CAPOX1 (N = 938)
FOLFOX42 (N = 1,108)
FLOX3 (N = 1,200)
Cross-trial comparison*Not reported
Neutropenia
Nausea
Stomatitis
Diarrhea
Febrile
neutropenia HFS
Vomiting
Neurose
nsory
1Schmiegel WH, et al. J Clin Oncol 2007;25(Suppl. 18):172s (Abstract 4034)2André T, et al. N Engl J Med 2004;350:2343–51
3Wolmark N, et al. J Clin Oncol 2005;23(Suppl. 16 Pt I):246s (Abstract LBA 3500)
*
Adjuvant CAPOX: Toxicity Compared with FOLFOX and FLOX
Adjuvant CAPOX: Toxicity Compared with FOLFOX and FLOX
* *
50
40
30
20
10
0
Ongoing US Cooperative Group Trials Adjuvant Therapy of Colon Cancer
Ongoing US Cooperative Group Trials Adjuvant Therapy of Colon Cancer
Stage III colon cancer (N = 2,300)
Stage II/III colon cancer (N = 2,400)
mFOLFOX6 6m
mFOLFOX6 6m +Bevacizumab 12m
Intergroup N0147
NSABP C-08
mFOLFOX6 6m
mFOLFOX6 6m +Cetuximab 6m
Accrual completed
Should Patients with Stage II Colon Cancer Receive Adjuvant Therapy?Should Patients with Stage II Colon Cancer Receive Adjuvant Therapy?
• Direct evidence of randomized trials
• Meta-analyses
• Identification of “high-risk” patients
• Direct evidence of randomized trials
• Meta-analyses
• Identification of “high-risk” patients
Approximate Number of Patients Needed to Detect a Realistic Treatment Benefit*
Dukes’ B Dukes’ C
No. of No. of Survival ARR Patients Survival ARR Patients
At 3-years 85% 2.5% 8,000 65% 5.2% 3,400
At 4-years 80% 3.3% 5,800 58% 6.0% 2,800
At 5-years 75% 4.0% 4,700 50% 6.6% 2,400
Abbreviation: ARR = absolute risk reduction
• For 90% power of detecting the treatment benefit using two-tailed significance tests at the 5% level, assuming the true relative risk reduction is 18% for both Dukes’ B and Dukes’ C.
Buyse, Piedbois, 2001
QUASAR: Study DesignQUASAR: Study Design
Clear indication for chemotherapy
(N = 4,320)
2 x 2 randomization to 5-FU with low- or high-dose LV and
Lev or placebo
Chemotherapy(N = 1,622)*
Observation(N = 1,617)No clear indication
for chemotherapy(mainly stage II)
(N = 3,239)
RANDOMIZE
Colon or rectal cancer
• Stage I-III• Complete resection
with no evidence of residual disease
* Prior to 10/1997 chemotherapy patients were randomized as in clear indication arm; after 10/1997 patients received 5-FU/low-dose LV.
QUASAR Group, Lancet 2007
% o
f Pa
tien
tsQUASAR: Overall Survival in Patients with
“no clear indication for chemo”QUASAR: Overall Survival in Patients with
“no clear indication for chemo”
P = .025-year OS, Observation = 77.4% vs Chemotherapy = 80.3%Relative risk = 0.83 (95% CI, 0.71-0.97)
YearsQUSAR group, Lancet 2007
0 1 2 3 4 5 6 7 8 9 100
20
40
60
80
100Observation (N = 1,622)
Chemotherapy (N = 1,617)
5-yr OS difference: 2.9%
ASCO Guidelines 2004ASCO Guidelines 2004
• Direct evidence from randomized controlled trials does not support the routine use of adjuvant chemotherapy for patients with stage II colon cancer.
• Patients and oncologists who accept the relative benefit in stage III disease as adequate indirect evidence of benefit for stage II disease are justified in considering the use of adjuvant chemotherapy, particularly for those patients with high-risk stage II disease.
• The ultimate clinical decision should be based on discussions with the patient about the nature of the evidence supporting treatment, the anticipated morbidity of treatment, the presence of high-risk prognostic features on individual prognosis, and patient preferences.
• Patients with stage II disease should be encouraged to participate in randomized trials.
• Direct evidence from randomized controlled trials does not support the routine use of adjuvant chemotherapy for patients with stage II colon cancer.
• Patients and oncologists who accept the relative benefit in stage III disease as adequate indirect evidence of benefit for stage II disease are justified in considering the use of adjuvant chemotherapy, particularly for those patients with high-risk stage II disease.
• The ultimate clinical decision should be based on discussions with the patient about the nature of the evidence supporting treatment, the anticipated morbidity of treatment, the presence of high-risk prognostic features on individual prognosis, and patient preferences.
• Patients with stage II disease should be encouraged to participate in randomized trials.
Benson et al. J Clin Oncol. 2004
“High-risk” Stage II Colon Cancer“High-risk” Stage II Colon Cancer
• Clinico-pathological parameters
• T4 tumors
• Obstruction/perforation
• Lymphatic or vascular invasion
• Undifferentiated histology
• Less than 10 (12) Ln examined
• Molecular parameters
• LOH 18q
• MSS
• Other?
• Clinico-pathological parameters
• T4 tumors
• Obstruction/perforation
• Lymphatic or vascular invasion
• Undifferentiated histology
• Less than 10 (12) Ln examined
• Molecular parameters
• LOH 18q
• MSS
• Other?
Analysis of Molecular Markers in Patients with Stage III Colon Cancer
Watanbe T, et al. N Engl J Med 344(16);1196-1206, 2001
Colon Stage II – AdjuvantE5202: High Risk Stage IIColon Stage II – AdjuvantE5202: High Risk Stage II
Register
Tumor block assessmentfor 18q/MSI
High Risk• MSS + 18q LOH• MSI-L + 18q LOH
Low Risk• MSS, no 18q LOH• MSI-L, no 18q LOH• MSI-H +/- 18q LOH
Observation
mFOLFOX6
mFOLFOX6+ bevacizumab
R
Expect 2 weeks for tissue review
N = 3,610
What is the Standard Adjuvant Therapy in Colon Cancer ?
What is the Standard Adjuvant Therapy in Colon Cancer ?
• FOLFOX is the standard adjuvant therapy in stage III and high-risk stage II colon cancer
• Capecitabine (UFT,S1?) for patients who are not considered candidates for oxaliplatin
• Irinotecan-based combinations are NOT options in the adjuvant setting
• XELOX data eagerly awaited
• Bevacizumab and Cetuximab are under investigation
• FOLFOX is the standard adjuvant therapy in stage III and high-risk stage II colon cancer
• Capecitabine (UFT,S1?) for patients who are not considered candidates for oxaliplatin
• Irinotecan-based combinations are NOT options in the adjuvant setting
• XELOX data eagerly awaited
• Bevacizumab and Cetuximab are under investigation